Ulcerative Colitis and the Role of S1P Receptor Modulators and JAK Inhibitors - A Wheel of Knowledge Challenge!

Overview

Provider Statement

This continuing education activity is provided by 

Support Statement

This activity is supported by an educational grant from Pfizer, Inc.

Activity Description

Ulcerative colitis (UC), a type of inflammatory bowel disease, is a chronic relapsing condition characterized by an overly active immune response in the large intestine, resulting in inflammation and ulceration. Given the increasing prevalence of disease and rapid influx of available biologics and small molecule therapies, there is great need for ongoing education regarding new and emerging treatment approaches for the management of UC. In this continuing education program, expert clinicians will discuss the role of sphingosine-1-phosphate (S1P) and Janus kinase (JAK) signaling in the pathophysiology and treatment of UC. Faculty will evaluate the safety and efficacy of current and emerging therapies and discuss optimal positioning of S1P receptor modulators and JAK inhibitors in the shifting UC treatment paradigm. This program will include case-based discussion and the unique, audience-engaging educational gaming platform, A Wheel of Knowledge Challenge.

Target Audience

The intended audience for this activity includes gastroenterologists, internists, primary care physicians, nurses, nurse practitioners, physician associates, and other healthcare professionals involved in the management of patients with ulcerative colitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess the mechanisms of action of sphingosine-1-phosphate (S1P) signaling molecules and significance in the pathophysiology of ulcerative colitis (UC).
• Describe the role of S1P receptor modulators in the current UC treatment paradigm and the recent clinical evidence regarding their safety and efficacy in patients with moderate-to-severe disease.
• Identify the current and investigational JAK inhibitors to treat ulcerative colitis and the role of JAK selectivity in the pathophysiology of the condition.

Activity Chair

Corey A. Siegel, MD, MS
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, Inflammatory Bowel Disease Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Faculty

Silvio Danese, MD, PhD
Director, Gastroenterology and Endoscopy
IRCCS Ospedale San Raffaele
Professor of Gastroenterology
University Vita-Salute San Raffaele
Milan, Italy

Millie D. Long, MD, MPH
Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC

Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This enduring material is approved for 1 year from the date of original release, June 13, 2023, to June 12, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Silvio Danese, MD, PhD
Consultant: AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Hospira, Janssen, Johnson & Johnson, Lilly, Mylan, Pfizer, Sandoz, Takeda, TiGenix, UCB
Speaker Contracted by Ineligible Company: AbbVie, Amgen, Ferring, Janssen, Mylan, Pfizer, Takeda

Millie D. Long, MD, MPH
Consultant: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda
Independent Research Contractor: Pfizer, Takeda

Bruce E. Sands, MD, MS
Consultant: AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Galapagos, Janssen, Lilly, Pfizer, Takeda
Speaker Contracted by Ineligible Company: Bristol Meyers Squibb, Janssen, Lilly, Pfizer, Takeda
Independent Research Contractor: Janssen

Corey A. Siegel, MD, MS
Consultant: AbbVie, Bristol Myers Squibb, Celltrion, Fresenius, Janssen, Lilly, Pfizer, Takeda
Independent Research Contractor: AbbVie, Janssen, Pfizer, Takeda

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this web activity is available upon request. Requests should include the web activity title and emailed to cme@vindicoCME.com. Requests will be honored within 3 to 5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com